We examined effects of a putative myosin light chain kinase inhibitor in the cerebral circulation in vivo. In anesthetized rats, diameter of basilar arteries was measured through a cranial window (control, 232±10 (im, mean±SEM). Vessel diameter was measured during topical application of agonists and antagonists. ML-7, which has been reported to compete with adenosine triphosphate for binding to the catalytic site on myosin light chain kinase, attenuated vasoconstriction in response to prostaglandin F 2a (10~6 M; -22±1% before versus -14±1% and -3±2% during ML-7, 10" 7 and 10"' M, respectively; p<0.05). ML-7 (10~6 M) did not affect baseline diameter. Responses to serotonin (10~8 M) and phorbol 12,13-dibutyrate (10~8 M) were not attenuated by ML-7. Thus, constriction of the basilar artery induced by prostaglandin ¥ la in vivo is attenuated by an inhibitor of myosin light chain kinase. (Hypertension 1992;19:739-742) KEY WORDS • prostaglandins • dinoprost • serotonin • phorbol esters
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We examined effects of a putative myosin light chain kinase inhibitor in the cerebral circulation in vivo.
In anesthetized rats, diameter of basilar arteries was measured through a cranial window (control, 232±10 (im, mean±SEM). Vessel diameter was measured during topical application of agonists and antagonists. ML-7, which has been reported to compete with adenosine triphosphate for binding to the catalytic site on myosin light chain kinase, attenuated vasoconstriction in response to prostaglandin F 2a (10~6 M; -22±1% before versus -14±1% and -3±2% during ML-7, 10" 7 and 10"' M, respectively; p<0.05). ML-7 (10~6 M) did not affect baseline diameter. Responses to serotonin (10~8 M) and phorbol 12,13-dibutyrate (10~8 M) were not attenuated by ML-7. Thus, constriction of the basilar artery induced by prostaglandin ¥ la in vivo is attenuated by an inhibitor of myosin light chain kinase. 3 Protein kinase C phosphorylates the 20,000-D light chain of myosin at a different site than that phosphorylated by myosin light chain kinase. 4 It is not certain whether phosphorylation of myosin light chain by protein kinase C mediates smooth muscle contraction induced by phorbol esters or whether other effects of phorbol esters are responsible for the contraction. 5 Some studies 3 -4 suggest that vasoconstriction may be produced by different signal transduction pathways. Concordant with this hypothesis is the finding that inhibitors of protein kinase C block constrictor responses to serotonin and phorbol dibutyrate but not to prostaglandin (PG)F 2a . 6 The goal of the current study was to examine the effects of an inhibitor of myosin light chain kinase on constriction of the basilar artery. We used ML-7 (l-[5-iodonaphthalene-l-sulfonyl]-lH-hexahydro-l,4-diazepine hydrochloride), which has been reported to com-pete with adenosine triphosphate for binding to the catalytic site on myosin light chain kinase.
7
- 8 We anticipated that, although constriction of the basilar artery in response to PGF 2a is resistant to inhibitors of protein kinase C, 6 the response might be inhibited by ML-7.
Methods

Animal Preparation
Experiments were performed on 20 male SpragueDawley rats (270-500 g) anesthetized with pentobarbital sodium (50 mg/kg i.p.). Animals underwent tracheotomy and were mechanically ventilated with room air and supplemental oxygen. A femoral vein was cannulated for drug infusion. Skeletal muscle paralysis was produced with gallamine triethiodide (5-10 mg/kg). Because the animals were paralyzed, we evaluated them approximately every 30 minutes for adequacy of anesthesia. When pressure to a paw evoked a change in blood pressure, additional anesthesia was administered at a rate of approximately 20 mg/kg/hr. A femoral artery was cannulated to measure systemic arterial pressure and to obtain arterial blood. Arterial blood gases were monitored and maintained within normal limits throughout the experiment (Pco 2 , 39±1 [±SEM] mm Hg; Po 2 , 135±7 mm Hg; pH 7.37±0.02).
A craniotomy was prepared over the ventral brain stem as described previously, 9 and a portion of the dura mater was opened. The cranial window was suffused with artificial cerebrospinal fluid at 37°C that was bubbled continuously with 95% nitrogen and 5% carbon dioxide. In cerebrospinal fluid sampled from the cranial windows, Pco 2 was 40 ± 1 mm Hg, Po 2 was 59 ±2 mm Hg, and pH was 7.30±0.01. Diameter of blood vessels was measured with an Olympus stereomicroscope (model SZH, Leeds Precision Instruments, Inc., Minneapolis, Minn.) equipped with a television camera coupled to a video monitor and image-shearing device (model 908, Instrumentation for Physiology & Medicine, Inc., San Diego, Calif.). Total magnification of the system was x 168. The images were recorded on videotape for later analysis.
Vessel diameter was measured before and during application of each agonist and antagonist.
Drugs
The following agents were used: 9,11-dideoxy-lla, 9a-epoxymethano-prostaglandin F^ was purchased from Upjohn Diagnostics, Kalamazoo, Mich. 5-Hydroxytryptamine, phorbol 12,13-dibutyrate (PDBu), ML-7, bovine serum albumin (BSA, fraction V), and dimethyl sulfoxide (DMSO) were purchased from Sigma Chemical Co., St. Louis, Mo. Stock solutions of PDBu and ML-7 were dissolved in DMSO and stored as aliquots at -20°C. PDBu and ML-7 were diluted in 1% BSA, and PGF^ and serotonin were diluted in physiological saline. The solvents (DMSO, BSA, and saline) did not affect diameter of the basilar artery at the concentrations used.
Effects of Prostaglandin F 2a
PGF^ was administered into the suffusate for 5 minutes to produce a final molar concentration of 10~6 in the cranial window. The concentration of 10~* M PGF^ was chosen from the middle of the concentration-response curve, based on our previous study. 6 Diameter of the basilar artery was measured immediately before and during application of PGF^. After application of PGF^, vessel diameter returned to control values during a 20-30-minute recovery period.
We examined the effect of ML-7 on responses to PGF^. PGF^ (10~6) was administered into the suffusate for 5 minutes, and vessel diameter was measured. Twenty to 30 minutes after stimulation with PGF^ and after vessel diameter had returned to control values, ML-7 (10~7 M, n=9; 10" 6 M, n = \0) was suffused over the cranial window for 10 minutes, followed by administration of PGF^ for 5 minutes in the presence of ML-7. Approximately 45 minutes later, PGF^ was applied during a recovery period, after ML-7 had been removed from the suffusate, to determine whether there was tachyphylaxis to PGF^.
In three experiments, we examined effects of vehicle, DMSO (0.1% by volume in 1% BSA), on responses to PGF^ (10"* M). PGF^-induced constriction was measured alone and in the presence of DMSO.
Effects of Serotonin
We tested the specificity of ML-7 (10~6 M) by examining its effect on serotonin-induced constriction in nine experiments. Serotonin (10~8 M) was administered into the suffusate for 5 minutes, and vessel diameter was measured. The concentration of serotonin (10~8 M) is in the middle of the concentration-response curve. 6 After stimulation with serotonin, vessel diameter returned to control values within 20-30 minutes. ML-7 was then suffused over the cranial window for 10 minutes, followed by stimulation with serotonin for 5 minutes in the presence of ML-7.
Effects of Phorbol Dibutyrate
We also tested the specificity of ML-7 with PDBu, a direct activator of protein kinase C. 10 " PDBu (10~8 M, n=6) was suffused continuously over the window for 60 minutes, and vessel diameter was measured. Phorbol esters persist in the cell membrane for long periods of time because they are metabolized slowly. 12 For this reason, PDBu was applied to the basilar artery only once during an experiment, either alone or in the presence of ML-7.
In seven experiments, we examined the effect of ML-7 (10"* M) on PDBu-induced constriction. ML-7 was suffused over the window for 10 minutes, followed by suffusion of PDBu (10~8 M) for 60 minutes in the presence of ML-7. Vessel diameter was measured before and during application of ML-7 and PDBu.
Analysis of Data
Statistical comparisons between paired values for responses to agonists from the same animal were made using a t test for paired comparisons. Comparisons between responses to PDBu alone and in the presence of ML-7 were evaluated with analysis of variance followed by a t test for unpaired comparisons. Similar results were obtained in comparing absolute changes or percent change. Data are presented as percent change. A value of p<0.05 was considered significant.
Results
During the initial exposure to PGF^ (10~6 M) and during the recovery period after ML-7, reductions in diameter were -2 2 ± 1 % and -22±2%. Thus, constriction of the basilar artery in response to PGF^ was reproducible, without evidence of tachyphylaxis.
ML-7 had no significant effect on baseline diameter (227±8 versus 225±8 fim at 10" 7 M ML-7; 224±11 /xm at 10" 6 M ML-7). ML-7 inhibited constriction of the basilar artery in response to PGF^ (Figure 1) . DMSO (0.1% by volume), the vehicle for ML-7, did not alter vasoconstriction in response to PGF^ (10~6 M; -2 1 ± 3 % before versus -20±4% during DMSO, n=3). Thus, attenuation of PGF^-induced constriction of the basilar artery after ML-7 was not due to effects of vehicle.
ML-7 did not attenuate serotonin-and PDBu-induced constriction of the basilar artery (Figure 1 ).
Discussion
The major new finding of this study is that constriction of the basilar artery in response to PGF^ was attenuated by the myosin light chain kinase inhibitor ML-7. This is the first report, to our knowledge, of the use of an inhibitor of myosin light chain kinase in cerebral vessels in vivo.
We considered the possibility that inhibition by ML-7 of PGF^-induced constriction may be related to nonspecific effects. We used serotonin and PDBu to test the specificity of the myosin light chain kinase inhibitor. Serotonin stimulates receptor-mediated hydrolysis of phosphoinositides by phospholipase C.
1J -' 6 Diacylglycerol is a product of phosphoinositide hydrolysis 17 and activates protein kinase C. 11 Our previous study 6 demonstrated that inhibitors of protein kinase C block serotonin-induced constriction of the rat basilar artery in vivo. Our present finding, that serotonin-induced constriction was not attenuated by ML-7, suggests that ML-7 did not nonselectively inhibit smooth muscle cell contraction.
Another study also suggests that ML-7 is relatively selective in inhibiting myosin light chain kinase. ML-7 effectively inhibited phosphorylation of myosin light chain in platelets stimulated with A23187.
l8 A23187 can elevate intracellular Ca 2+ levels in platelets without activating protein kinase C or phospholipase C, 19 resulting in activation of the Ca 2+ /calmodulin-dependent myosin light chain kinase.
PDBu, a protein kinase C activator, 10 ' 11 also produced constriction of the basilar artery that was not attenuated by ML-7. In a previous study, 6 we demonstrated that phorbol-induced constriction of the basilar artery was significantly attenuated by inhibitors of protein kinase C. The present finding, that PDBu-induced constriction was not attenuated by ML-7, suggests that ML-7 selectively inhibited PGF^-induced constriction. The findings are in agreement with a recent study, in which the Ca 2+ /calmodulin inhibitor R24571 did not affect phorbol-induced constriction of the canine basilar artery in vitro. 20 The findings support the concept that activation of protein kinase C mediates responses to phorbol esters. ML-7 had no effect on baseline diameter of the basilar artery. A recent study also demonstrated that topical application of R24571, a calmodulin antagonist, produced no change in diameter of the canine basilar artery in vivo. 3 The findings suggest that the calmodulin/myosin light chain kinase pathway is not a necessary mediator of basal tone of the basilar artery in vivo.
These data suggest that agonist-induced vasoconstriction may be linked to different signal transduction pathways. The studies demonstrate that ML-7, an inhibitor of myosin light chain kinase, attenuates vasoconstriction in response to PGF^ but not in response to serotonin and PDBu. Although the data indicate that ML-7 was specific in inhibiting vasoconstrictor responses to PGF^, we cannot exclude the possibility that attenuation of responses to PGFi, by ML-7 were the result of inhibition of membrane receptors. If ML-7 acts by inhibiting myosin light chain kinase, it is not clear why vasoconstriction in response to serotonin was not also inhibited. It is possible that serotonin, in addition to stimulating receptor-mediated hydrolysis of phosphoinositides, 13 -16 also stimulates hydrolysis of phosphatidylcholine. Diacylgrycerol, which activates protein kinase C, 11 is generated by the hydrolysis of phosphatidylcholine and phosphoinositides. 2122 The presence of a large pool of diacylgrycerol may be the mechanism by which serotonin acts primarily through the protein kinase C pathway.
In summary, these experiments indicate that ML-7, which blocks the catalytic site on myosin light chain kinase, inhibits vasoconstriction in response to PGF^.
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